Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBITDA: 2017-2025

Historic EBITDA for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $9.6 million.

  • Puma Biotechnology's EBITDA fell 56.64% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of $31.0 million for FY2024, which is 5.13% down from last year.
  • Latest data reveals that Puma Biotechnology reported EBITDA of $9.6 million as of Q3 2025, which was up 44.26% from $6.6 million recorded in Q2 2025.
  • Puma Biotechnology's EBITDA's 5-year high stood at $22.1 million during Q3 2024, with a 5-year trough of -$16.6 million in Q2 2021.
  • Its 3-year average for EBITDA is $7.6 million, with a median of $6.6 million in 2025.
  • In the last 5 years, Puma Biotechnology's EBITDA slumped by 333.31% in 2021 and then surged by 2,091.25% in 2022.
  • Over the past 5 years, Puma Biotechnology's EBITDA (Quarterly) stood at -$503,000 in 2021, then skyrocketed by 2,091.25% to $10.0 million in 2022, then skyrocketed by 47.74% to $14.8 million in 2023, then declined by 9.68% to $13.4 million in 2024, then crashed by 56.64% to $9.6 million in 2025.
  • Its EBITDA stands at $9.6 million for Q3 2025, versus $6.6 million for Q2 2025 and $4.0 million for Q1 2025.